)
)
)
Gipfel Biotechnology Limited
Gipfel Biotechnology (Cayman-registered) is the 100% owner of Hangzhou Qiandai Biotechnology (est. 2023, Hangzhou). Our R&D portfolio covers two core areas:
- Innovative small-molecule drugs for ophthalmic diseases, autoimmune diseases, chronic kidney disease and hyperuricemia;
- Recombinant subunit vaccines targeting respiratory infections (e.g., Mycoplasma pneumoniae—a PCC-stage candidate with confirmed efficacy and safety).
To date, three proprietary pre-clinical candidates have advanced to PCC stage, with their efficacy and safety validated in animal models. Additional vaccine candidates are under screening to meet unmet medical needs.
Address
Hangzhou XiaoshanZhengjiang
China
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)